Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.

@article{Scharf2015MetabotropicGR,
  title={Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.},
  author={Sebastian Scharf and Georg Jaeschke and Joseph G. Wettstein and Lothar Lindemann},
  journal={Current opinion in pharmacology},
  year={2015},
  volume={20},
  pages={124-34}
}
Fragile X syndrome (FXS) is the most common monogenic form of inherited mental retardation caused by a trinucleotid repeat expansion and transcriptional shutdown of the FMR1 gene. FXS patients present a complex and often severe neuropsychiatric phenotype yet have mild somatic symptoms, normal life expectancies, and no indications of neurodegeneration. The therapeutic potential of mGlu5 inhibitors was proposed in the 'mGluR theory of FXS' based on early insights into the molecular… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
34 Citations
82 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 82 references

Discovery of the mGlu5 negative allosteric modulator basimglurant (RO4917523)

  • G Jaeschke, S Kolczewski, +7 authors M Schneider
  • Curr Neuropharmacol 2014, 12: 28. Abstract to a…
  • 2014

Similar Papers

Loading similar papers…